Trial Profile

SHIFT-IBD: Switching to High-efficacy Anti-IL-23 Guselkumab in Ustekinumab-exposed Persons With Active IBD

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Guselkumab (Primary)
Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
Focus Therapeutic Use
Acronyms SHIFT-IBD

Most Recent Events

06 Jan 2026 Planned initiation date changed from 29 Dec 2025 to 1 Sep 2026.
06 Jan 2026 Status changed from not yet recruiting to recruiting.
26 Dec 2025 Planned initiation date changed from 1 Dec 2025 to 29 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com